|
House Bill 21 |
House Author: Kacal et al. |
|
Effective: 6-16-15 |
Senate Sponsor: Bettencourt |
House Bill 21 establishes the Right to Try Act and amends the Health and Safety Code to establish the eligibility of a patient who has a terminal illness to access and use an investigational drug, biological product, or device, including requirements for a physician's recommendations and a patient's informed consent. The bill requires a manufacturer that provides an eligible patient with the manufacturer's investigational drug, biological product, or device to do so without receiving compensation. The bill prohibits state interference with an eligible patient's access to an investigational drug, biological product, or device and prohibits the Texas Medical Board from taking action against a physician's license based solely on the physician's lawful recommendations to an eligible patient regarding access to or treatment with an investigational drug, biological product, or device.